Real‐world outcomes using the Tandem Mobi insulin pump with Control‐ IQ + technology and Dexcom G7
Authors' conclusion
These findings demonstrate safe and effective use of the Tandem Mobi insulin pump with Control-IQ+ technology paired with the Dexcom G7 sensor in the at-home, unsupervised setting.
Study context
- Population
- Users of the Tandem Mobi insulin pump with Control-IQ+ technology paired with the Dexcom G7 continuous glucose monitor (CGM), with ≥30 days of use of the combined system in the Tandem Source web applicationmedian 5.1 months of use
- Participants
- 29,265 users
- Exposure
- Adults vs Children 6-17 years vs Children 2-5 years
- Outcome
- TIR 3.9-10.0 mmol/L
Methodological detailspostmarket surveillance surveys
- Postmarket surveillance surveys
Main finding
As reported in the abstract
- CGM availability, overall median (exceeded 95% for all age groups)
- 97.8%
- Median time in closed loop
- 94.1%
Observational data: associations, not effects.
Further findings
Postmarket surveillance surveys
- Surveys completed by 1941 users reported high satisfaction with pump usability, CGM connectivity and the AID algorithm
Safety
- Time <3.9 mmol/L was low
- 1.4%
Original publication
Real‐world outcomes using the Tandem Mobi insulin pump with Control‐ IQ + technology and Dexcom G7. Diabet Med. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →